A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females

Exclusion Criteria

• •Healthy Participants (Part 1 only)
• •* Clinically significant abnormalities in laboratory test results or electrocardiogram
• •* History of significant allergies, gastrointestinal, renal, hepatic, cardiovascular, or pulmonary disease
• •* History of hypersensitivity or allergic reaction, spontaneous or following drug administration
• •* History of cardiac conditions
• •HER2-Positive Females (Parts 1 and 2)
• •* Metastatic disease
• •* Concurrent other malignancy requiring therapy of any modality which may interfere with PK investigations or result in unexpected toxicity
• •* Use of Herceptin in previous 5 months
• •* Serious cardiac illness